BeOne Medicines to present Phase 1 liver cancer drug data at ESMO 2026
ONC•BeOne Medicines will present solid-tumor clinical data at the ESMO Congress in Madrid from October 23-27, 2026, including early-stage data for BGB-B2033 in liver cancer and updated Phase 3 HERIZON-GEA-01 results.
1. Planned presentations
BeOne Medicines said it will present solid-tumor clinical data at the ESMO Congress in Madrid from October 23-27, 2026. Early-stage presentations will cover BGB-B2033 in liver cancer, BG-C477 in non-small cell lung cancer and BGB-58067 in MTAP-deficient tumors. The company also plans to present updated Phase 3 HERIZON-GEA-01 results evaluating Ziihera with chemotherapy, with or without Tevimbra, for first-line HER2-positive advanced gastroesophageal cancer.
